Indication and rivaroxaban dose | VTE prevention: | DVT treatment: | Prevention of stroke in patients with AF and CrCl ≥50 ml/min: | Prevention of stroke in patients with AF and CrCl <50 ml/min: | Prevention of CV events in patients with ACS: |
---|---|---|---|---|---|
10 mg od | 15 mg bid for 3 weeks followed by 20 mg od | 20 mg od | 15 mg od | 2.5 mg bid | |
Time after dosing (hours) | Concentration, μg/l (5/95 percentile) | Concentration, μg/l (5/95 percentile) | Concentration, μg/l (5/95 percentile) | Concentration, μg/l (5/95 percentile) | Concentration, μg/l (5/95 percentile) |
1 | 111 (75.1–177) | 235 (164–361) | 216 (152–316) | 189 (134–281) | 41.3 (23.5–65.9) |
2 | 122 (90.6–195) | 270 (189–419) | 250 (177–361) | 219 (157–317) | 44.1 (26.7–69.5) |
3 | 114 (82.3–186) | 259 (180–405) | 246 (172–361) | 216 (153–317) | 42.0 (25.9–66.4) |
4 | 102 (75.8–164) | 237 (161–369) | 232 (157–349) | 205 (141–309) | 38.7 (23.3–63.3) |
5 | 90.7 (62.2–143) | 213 (145–339) | 215 (140–333) | 191 (127–297) | 35.2 (20.2–59.1) |
6 | 80.2 (51.8–125) | 191 (123–311) | 198 (123–318) | 177 (111–286) | 31.7 (17.4–55.5) |
9 | 55.2 (30.5–96.0) | 137 (71.3–240) | 155 (81.9–276) | 141 (74.9–254) | 22.8 (10.4–45.2) |
12 | 37.8 (15.2–76.1) | 97.8 (42.9–190) | 121 (53.4–242) | 112 (50.0–225) | 16.2 (6.11–36.6) |
18 | 17.9 (4.85–49.9) | 50.0 (16.0–124) | 73.5 (22.0–187) | 70.4 (21.9–180) | − |
24 | 8.54 (1.36–37.2) | 25.6 (5.93–86.9) | 44.7 (9.02–147) | 44.4 (9.42–143) | − |